AbbVie (ABBV) FCF Margin Growth (1y) (2013 - 2026)
AbbVie (ABBV) FCF Margin Growth (1y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1,688.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1,334.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1,096.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -647.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -158.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1,388.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3,383.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1,020.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 69.00 |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 517.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,334.00 |
| Mar 31, 2026 | 1,326.00 |
| Dec 31, 2025 | -1,532.00 |
| Sep 30, 2025 | 616.00 |
| Jun 30, 2025 | 1,763.00 |
| Mar 31, 2025 | -2,076.00 |
| Dec 31, 2024 | 1,294.00 |
| Sep 30, 2024 | -1,686.00 |
| Jun 30, 2024 | -3,025.00 |
| Mar 31, 2024 | -162.00 |
| Dec 31, 2023 | -1,591.00 |
| Sep 30, 2023 | 268.00 |
| Jun 30, 2023 | 1,095.00 |
| Mar 31, 2023 | -219.00 |
| Dec 31, 2022 | 1,488.00 |
| Sep 30, 2022 | -369.00 |
| Jun 30, 2022 | -29.00 |
| Mar 31, 2022 | -98.00 |
| Dec 31, 2021 | -18.00 |
| Sep 30, 2021 | 1,031.00 |